Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results
Cerus (CERS) reported strong financial results for full-year and Q4 2024. Full-year product revenue reached $180.3 million, up 15% year-over-year, while Q4 product revenue was $50.8 million, a 9% increase. The company achieved significant financial improvements, including a 40% reduction in GAAP net loss to $20.9 million and positive non-GAAP adjusted EBITDA of $5.7 million for 2024.
Notable achievements include four consecutive quarters of positive operating cash flows, totaling $11.4 million for the year, a $55 million improvement from 2023. The INTERCEPT Fibrinogen Complex (IFC) product showed strong growth, with full-year revenue of $9.2 million, up 42% from the previous year.
The company reiterated its 2025 product revenue guidance of $194-200 million, including $12-15 million for IFC, projecting 8-11% growth from 2024.
Cerus (CERS) ha riportato risultati finanziari solidi per l'intero anno e il quarto trimestre del 2024. Il fatturato dei prodotti per l'intero anno ha raggiunto $180,3 milioni, con un aumento del 15% rispetto all'anno precedente, mentre il fatturato del quarto trimestre è stato di $50,8 milioni, un incremento del 9%. L'azienda ha ottenuto significativi miglioramenti finanziari, inclusa una riduzione del 40% della perdita netta GAAP a $20,9 milioni e un EBITDA rettificato non GAAP positivo di $5,7 milioni per il 2024.
Tra i risultati notevoli ci sono quattro trimestri consecutivi di flussi di cassa operativi positivi, per un totale di $11,4 milioni per l'anno, con un miglioramento di $55 milioni rispetto al 2023. Il prodotto INTERCEPT Fibrinogen Complex (IFC) ha mostrato una forte crescita, con un fatturato annuale di $9,2 milioni, in aumento del 42% rispetto all'anno precedente.
L'azienda ha ribadito la sua guida per il fatturato dei prodotti del 2025 di $194-200 milioni, inclusi $12-15 milioni per l'IFC, prevedendo una crescita dell'8-11% rispetto al 2024.
Cerus (CERS) reportó resultados financieros sólidos para el año completo y el cuarto trimestre de 2024. Los ingresos por productos para el año completo alcanzaron $180.3 millones, un aumento del 15% interanual, mientras que los ingresos por productos del cuarto trimestre fueron de $50.8 millones, un incremento del 9%. La compañía logró mejoras financieras significativas, incluyendo una reducción del 40% en la pérdida neta GAAP a $20.9 millones y un EBITDA ajustado no GAAP positivo de $5.7 millones para 2024.
Los logros notables incluyen cuatro trimestres consecutivos de flujos de caja operativos positivos, totalizando $11.4 millones para el año, una mejora de $55 millones respecto a 2023. El producto INTERCEPT Fibrinogen Complex (IFC) mostró un fuerte crecimiento, con ingresos anuales de $9.2 millones, un aumento del 42% respecto al año anterior.
La compañía reiteró su guía de ingresos por productos para 2025 de $194-200 millones, incluyendo $12-15 millones para IFC, proyectando un crecimiento del 8-11% respecto a 2024.
Cerus (CERS)는 2024년 전체 및 4분기 강력한 재무 실적을 보고했습니다. 전체 연도 제품 수익은 $180.3 백만에 달해 전년 대비 15% 증가했으며, 4분기 제품 수익은 $50.8 백만으로 9% 증가했습니다. 회사는 GAAP 기준 순손실을 $20.9 백만으로 40% 줄이는 등 상당한 재무 개선을 이루었으며, 2024년 비GAAP 조정 EBITDA는 $5.7 백만을 기록했습니다.
주목할 만한 성과로는 4분기 연속으로 긍정적인 운영 현금 흐름을 기록하여 연간 총 $11.4 백만을 달성한 것이 있으며, 이는 2023년 대비 $55 백만의 개선입니다. INTERCEPT Fibrinogen Complex (IFC) 제품은 강력한 성장을 보여주었으며, 전체 연도 수익은 $9.2 백만으로 전년 대비 42% 증가했습니다.
회사는 2025년 제품 수익 가이던스를 $194-200 백만으로 재확인했으며, IFC에 대해 $12-15 백만을 포함하여 2024년 대비 8-11%의 성장을 예상하고 있습니다.
Cerus (CERS) a rapporté des résultats financiers solides pour l'année complète et le quatrième trimestre 2024. Les revenus des produits pour l'année complète ont atteint $180,3 millions, en hausse de 15 % par rapport à l'année précédente, tandis que les revenus des produits du quatrième trimestre s'élevaient à $50,8 millions, soit une augmentation de 9 %. L'entreprise a réalisé des améliorations financières significatives, notamment une réduction de 40 % de la perte nette GAAP à $20,9 millions et un EBITDA ajusté non GAAP positif de $5,7 millions pour 2024.
Parmi les réalisations notables figurent quatre trimestres consécutifs de flux de trésorerie d'exploitation positifs, totalisant $11,4 millions pour l'année, une amélioration de 55 millions de dollars par rapport à 2023. Le produit INTERCEPT Fibrinogen Complex (IFC) a montré une forte croissance, avec un chiffre d'affaires annuel de $9,2 millions, en hausse de 42 % par rapport à l'année précédente.
L'entreprise a réitéré ses prévisions de revenus produits pour 2025 de $194-200 millions, y compris 12 à 15 millions de dollars pour l'IFC, prévoyant une croissance de 8 à 11 % par rapport à 2024.
Cerus (CERS) berichtete über starke finanzielle Ergebnisse für das Gesamtjahr und das vierte Quartal 2024. Der Produktumsatz für das Gesamtjahr erreichte $180,3 Millionen, was einem Anstieg von 15% im Vergleich zum Vorjahr entspricht, während der Produktumsatz im vierten Quartal $50,8 Millionen betrug, ein Anstieg von 9%. Das Unternehmen erzielte bedeutende finanzielle Verbesserungen, darunter eine Reduzierung des GAAP-Nettoverlusts um 40% auf $20,9 Millionen sowie ein positives nicht-GAAP bereinigtes EBITDA von $5,7 Millionen für 2024.
Bemerkenswerte Erfolge sind vier aufeinanderfolgende Quartale mit positiven operativen Cashflows, die insgesamt $11,4 Millionen für das Jahr betrugen, was eine Verbesserung um $55 Millionen im Vergleich zu 2023 darstellt. Das Produkt INTERCEPT Fibrinogen Complex (IFC) zeigte ein starkes Wachstum mit einem Jahresumsatz von $9,2 Millionen, was einem Anstieg von 42% im Vergleich zum Vorjahr entspricht.
Das Unternehmen bestätigte seine Umsatzprognose für Produkte im Jahr 2025 von $194-200 Millionen, einschließlich $12-15 Millionen für IFC, mit einer erwarteten Wachstumsrate von 8-11% im Vergleich zu 2024.
- Product revenue growth of 15% to $180.3M for full-year 2024
- 40% improvement in GAAP net loss from $37.5M to $20.9M
- Positive non-GAAP adjusted EBITDA of $5.7M in 2024
- Generated $11.4M in positive operating cash flows
- IFC product revenue grew 42% to $9.2M
- 8% reduction in operating expenses year-over-year
- Q4 2024 product gross margin decreased to 53.9% from 55.5%
- Government contract revenue declined to $21.1M from $30.4M
- Q4 2024 net loss increased to $2.5M from $1.3M in Q4 2023
- $84.3M in total debt outstanding ($65M term loan + $19.3M revolving credit)
Insights
Cerus 's 2024 results reveal a compelling transformation story, marked by robust operational execution and financial discipline. The
The achievement of positive non-GAAP adjusted EBITDA of
The balance sheet shows increasing strength with
Looking ahead, the 2025 revenue guidance of
Full-Year and Fourth Quarter 2024 Product Revenues Increased
Fourth straight quarter of positive operating cash flows
Reiterating Full-Year 2025 Product Revenue Guidance Range of
Recent highlights include:
- Total revenue for full-year 2024 and fourth quarter 2024 was comprised of (in thousands, except %):
Three Months Ended |
|
|
|
|
|
Twelve Months Ended |
|
|
|
|
|||||||||||||||
December 31, |
|
Change |
|
December 31, |
|
Change |
|||||||||||||||||||
|
Unaudited |
|
|
|
|
|
Unaudited |
|
|
|
|
|
|
||||||||||||
|
2024 |
|
|
2023 |
|
$ |
|
% |
|
2024 |
|
2023 |
|
$ |
|
% |
|||||||||
Product Revenue |
$ |
50,809 |
|
$ |
46,768 |
|
$ |
4,041 |
|
|
9 |
% |
|
$ |
180,270 |
|
$ |
156,367 |
|
$ |
23,903 |
|
|
15 |
% |
Government Contract Revenue |
|
5,942 |
|
|
6,574 |
|
|
(632 |
) |
|
-10 |
% |
|
|
21,051 |
|
|
30,430 |
|
|
(9,379 |
) |
|
-31 |
% |
Total Revenue |
$ |
56,751 |
|
$ |
53,342 |
|
$ |
3,409 |
|
|
6 |
% |
|
$ |
201,321 |
|
$ |
186,797 |
|
$ |
14,524 |
|
|
8 |
% |
-
The Company is reiterating its full-year 2025 annual product revenue guidance range of
to$194 million , which includes$200 million to$12 million for INTERCEPT Fibrinogen Complex (IFC).$15 million -
Continued financial execution for full year and Q4 2024:
-
Over
40% improvement in 2024 GAAP net loss attributable to Cerus Corporation to from$20.9 million for the previous year.$37.5 million -
Achieved positive non-GAAP adjusted EBITDA of
for 2024, outperforming against the stated objective of break-even adjusted EBITDA.$5.7 million -
Generated positive operating cash flows for the fourth straight quarter of 2024 bringing year-to-date positive operating cash flows to
, an improvement of almost$11.4 million from 2023.$55.0 million
-
Over
“Our exceptional fourth quarter performance capped a year of significant growth for Cerus, positioning us well for 2025 and beyond. INTERCEPT double-digit product revenue growth in 2024 reflects the continued momentum of our platelets business and rising clinical demand for our IFC product, underscoring the expanding impact of our pathogen inactivation technology in transfusion medicine,” stated William “Obi” Greenman, Cerus’ president and chief executive officer.
“Beyond our top-line growth, we delivered robust financial results, narrowing our GAAP net loss and achieving our communicated target of positive non-GAAP adjusted EBITDA for 2024 - key metrics we remain committed to improving. After achieving positive adjusted EBITDA in 2024 and projecting growth based on our 2025 product revenue guidance, we anticipate leveraging the inherent strengths of our business for continued financial improvement. With a multi-billion dollar total addressable market for existing approved products, enduring customer trust and a first-mover advantage, we believe we are setting new standards in blood safety and are well-positioned for continued success.”
Revenue
Product revenue for the full year 2024 was
Government contract revenue for the full year 2024 was
Product Gross Profit & Margin
Full-year 2024 product gross profit was
Product gross profit for the fourth quarter of 2024 was
Operating Expenses
Total operating expenses for the year declined over
R&D expenses for the full year 2024 were down
Full-year 2024 SG&A expenses were
Net Loss Attributable to Cerus Corporation
Net loss attributable to Cerus Corporation for full-year 2024 was
Non-GAAP Adjusted EBITDA
Importantly, the Company not only outperformed on the top-line but also achieved its other stated 2024 goal of reaching positive non-GAAP adjusted EBITDA, which was a positive
Balance Sheet & Cash Flows
At December 31, 2024, the Company had cash and cash equivalents and short-term investments of
As of December 31, 2024, the Company had
For full-year 2024, the Company generated positive operating cash flows of
Reiterating 2025 Product Revenue Guidance
The Company expects full-year 2025 product revenue will be in the range of
Quarterly Conference Call
The Company will host a conference call at 4:30 P.M. EST this afternoon, during which management will discuss the Company’s financial results and provide a general business overview and outlook. To listen to the live webcast, please visit the Investor Relations page of the Cerus website at http://www.cerus.com/ir.
A replay will be available on Cerus’ website approximately three hours after the call through March 6, 2025.
ABOUT CERUS
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in
INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.
Forward- Looking Statements
Except for the historical statements contained herein, this press release contains forward-looking statements concerning Cerus’ products, prospects and expected results, including statements relating to: Cerus’ 2025 annual product revenue guidance and related projected growth; Cerus’ belief that it is setting new standards in blood safety and is well-positioned for continued success; Cerus’ market opportunity, including its estimated total addressable market; Cerus’ expectation for continued financial improvement; Cerus’ expectation to continue seeing significant leverage in SG&A expenses with costs rising modestly relative to the expected revenue growth; Cerus’ expectations for improvements to GAAP net loss attributable to Cerus Corporation for the full-year 2025 and that it will maintain a positive non-GAAP adjusted EBITDA for the full-year 2025; Cerus continuing to have access to
Use of Non-GAAP Financial Measures
We define adjusted EBITDA as net loss attributable to Cerus Corporation as reported on the consolidated statement of operations, as adjusted to exclude, as applicable for the reporting period(s) presented, (i) net loss attributable to noncontrolling interest, (ii) provision for income taxes, (iii) foreign exchange (loss)/gain, (iv) interest income (expense), (v) other income (expense), net, (vi) depreciation and amortization, (vii) share-based compensation, (viii) goodwill and asset impairments, (ix) costs associated with our noncontrolling interest in our joint venture in
Investors should note that Cerus has not provided a reconciliation of anticipated positive non-GAAP adjusted EBITDA for the year ending December 31, 2025 to projected GAAP net loss attributable to Cerus Corporation for the year ending December 31, 2025 because certain items such as share-based compensation that are components of GAAP net loss attributable to Cerus Corporation cannot be reasonably projected due to the significant impact of changes in Cerus’ stock price and other factors. These components of GAAP net loss attributable to Cerus Corporation could significantly impact the reported GAAP net loss attributable to Cerus Corporation.
Supplemental Tables
|
Three Months Ended |
Twelve Months Ended |
|
December 31, |
December 31, |
|
2024 vs. 2023 |
2024 vs. 2023 |
Platelet Kit Growth |
|
|
|
|
|
International |
|
|
Worldwide |
|
|
|
|
|
Change in Calculated Number of Treatable Platelet Doses |
|
|
|
|
|
International |
|
|
Worldwide |
|
|
* Dose treatable calculation based on the number of kits sold and the product configuration (single, double, and triple dose kits) |
||
CERUS CORPORATION REVENUE BY REGION (in thousands, except percentages) |
|||||||||||||||||||||||||
|
Three Months Ended |
|
|
|
|
|
Twelve Months Ended |
|
|
|
|
||||||||||||||
|
December 31, |
|
Change |
|
December 31, |
|
Change |
||||||||||||||||||
|
Unaudited |
|
|
|
|
|
Unaudited |
|
|
|
|
|
|
||||||||||||
|
|
2024 |
|
|
2023 |
|
$ |
|
% |
|
2024 |
|
2023 |
|
$ |
|
% |
||||||||
|
$ |
34,011 |
|
$ |
32,110 |
|
$ |
1,901 |
|
|
6 |
% |
|
$ |
121,794 |
|
$ |
99,187 |
|
$ |
22,607 |
|
|
23 |
% |
|
|
16,081 |
|
|
13,833 |
|
|
2,248 |
|
|
16 |
% |
|
|
56,327 |
|
|
55,008 |
|
|
1,319 |
|
|
2 |
% |
Other |
|
717 |
|
|
825 |
|
|
(108 |
) |
|
-13 |
% |
|
|
2,149 |
|
|
2,172 |
|
|
(23 |
) |
|
-1 |
% |
Total product revenue |
$ |
50,809 |
|
$ |
46,768 |
|
$ |
4,041 |
|
|
9 |
% |
|
$ |
180,270 |
|
$ |
156,367 |
|
$ |
23,903 |
|
|
15 |
% |
CERUS CORPORATION CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except per share data) |
|||||||||||||||||||||
Three Months Ended |
|
Twelve Months Ended |
|
||||||||||||||||||
December 31, |
|
December 31, |
|
||||||||||||||||||
|
|
Unaudited |
|
Unaudited |
|
|
|
||||||||||||||
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
|
||||||
Product revenue |
$ |
50,809 |
|
|
$ |
46,768 |
|
|
$ |
180,270 |
|
|
$ |
156,367 |
|
|
|||||
Cost of product revenue |
|
23,424 |
|
|
|
20,809 |
|
|
|
80,748 |
|
|
|
69,967 |
|
|
|||||
Gross profit on product revenue |
|
27,385 |
|
|
|
25,959 |
|
|
|
99,522 |
|
|
|
86,400 |
|
|
|||||
Government contract revenue |
|
5,942 |
|
|
|
6,574 |
|
|
|
21,051 |
|
|
|
30,430 |
|
|
|||||
Operating expenses: |
|
|
|
|
|
|
|
|
|||||||||||||
Research and development |
|
15,443 |
|
|
|
14,288 |
|
|
|
58,907 |
|
|
|
67,639 |
|
|
|||||
Selling, general and administrative |
|
19,333 |
|
|
|
17,269 |
|
|
|
75,891 |
|
|
|
75,516 |
|
|
|||||
Restructuring |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
3,728 |
|
|
|||||
Total operating expenses |
|
34,776 |
|
|
|
31,557 |
|
|
|
134,798 |
|
|
|
146,883 |
|
|
|||||
(Loss) Gain from operations |
|
(1,449 |
) |
|
|
976 |
|
|
|
(14,225 |
) |
|
|
(30,053 |
) |
|
|||||
Total non-operating expense, net |
|
(1,002 |
) |
|
|
(2,293 |
) |
|
|
(6,531 |
) |
|
|
(7,269 |
) |
|
|||||
Loss before income taxes |
|
(2,451 |
) |
|
|
(1,317 |
) |
|
|
(20,756 |
) |
|
|
(37,322 |
) |
|
|||||
Provision for income taxes |
|
111 |
|
|
|
72 |
|
|
|
205 |
|
|
|
325 |
|
|
|||||
Net loss |
|
(2,562 |
) |
|
|
(1,389 |
) |
|
|
(20,961 |
) |
|
|
(37,647 |
) |
|
|||||
Net loss attributable to noncontrolling interest |
|
(41 |
) |
|
|
(61 |
) |
|
|
(43 |
) |
|
|
(158 |
) |
|
|||||
Net loss attributable to Cerus Corporation |
$ |
(2,521 |
) |
|
$ |
(1,328 |
) |
|
$ |
(20,918 |
) |
|
$ |
(37,489 |
) |
|
|||||
Net loss per share attributable to Cerus Corporation: |
|
|
|
|
|
|
|
|
|||||||||||||
Basic and diluted |
$ |
(0.01 |
) |
|
$ |
(0.01 |
) |
|
$ |
(0.11 |
) |
|
$ |
(0.21 |
) |
|
|||||
Weighted average shares outstanding: |
|
|
|
|
|
|
|
|
|||||||||||||
Basic and diluted |
|
185,734 |
|
|
|
181,216 |
|
|
|
184,563 |
|
|
|
180,270 |
|
|
|||||
CERUS CORPORATION CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) |
||||||
December 31, |
|
December 31, |
||||
2024 |
|
2023 |
||||
ASSETS |
(unaudited) |
|||||
Current assets: |
||||||
Cash and cash equivalents |
$ |
20,266 |
$ |
11,647 |
||
Short-term investments |
|
60,186 |
|
54,205 |
||
Accounts receivable, net |
|
29,777 |
|
35,500 |
||
Current inventories |
|
38,150 |
|
39,868 |
||
Prepaid and other current assets |
|
3,643 |
|
3,221 |
||
Total current assets |
|
152,022 |
|
144,441 |
||
Non-current assets: |
|
|||||
Property and equipment, net |
|
7,154 |
|
8,640 |
||
Operating lease right-of-use assets |
|
8,384 |
|
10,713 |
||
Goodwill |
|
1,316 |
|
1,316 |
||
Non-current inventories |
|
14,145 |
|
19,501 |
||
Other assets and restricted cash |
|
17,896 |
|
13,137 |
||
Total assets |
$ |
200,917 |
$ |
197,748 |
||
|
||||||
LIABILITIES AND STOCKHOLDERS' EQUITY |
|
|||||
Current liabilities: |
|
|||||
Accounts payable and accrued liabilities |
$ |
40,638 |
$ |
43,067 |
||
Debt – current |
|
19,297 |
|
20,000 |
||
Operating lease liabilities – current |
|
2,275 |
|
2,452 |
||
Deferred revenue – current |
|
1,398 |
|
2,002 |
||
Total current liabilities |
|
63,608 |
|
67,521 |
||
Non-current liabilities: |
|
|||||
Debt – non-current |
|
64,862 |
|
59,796 |
||
Operating lease liabilities – non-current |
|
11,663 |
|
13,751 |
||
Other non-current liabilities |
|
3,888 |
|
3,236 |
||
Total liabilities |
|
144,021 |
|
144,304 |
||
Stockholders' equity: |
|
56,145 |
|
52,650 |
||
Noncontrolling interest |
|
751 |
|
794 |
||
Total liabilities and stockholders' equity |
$ |
200,917 |
$ |
197,748 |
||
|
CERUS CORPORATION UNAUDITED RECONCILIATION OF NON-GAAP ADJUSTED EBITDA (in thousands) |
||||||||||||||||
Three Months Ended |
|
Twelve Months Ended |
||||||||||||||
December 31, |
|
December 31, |
||||||||||||||
|
2024 |
|
|
|
2023 |
|
|
|
2024 |
|
|
|
2023 |
|
||
Net loss attributable to Cerus Corporation |
$ |
(2,521 |
) |
|
$ |
(1,328 |
) |
|
$ |
(20,918 |
) |
|
$ |
(37,489 |
) |
|
|
|
|
|
|
|
|
||||||||||
Adjustments to net loss attributable to Cerus Corporation: |
|
|
|
|
|
|
|
|||||||||
Net loss attributable to noncontrolling interest |
|
(41 |
) |
|
|
(61 |
) |
|
|
(43 |
) |
|
|
(158 |
) |
|
Provision for income taxes |
|
111 |
|
|
|
72 |
|
|
|
205 |
|
|
|
325 |
|
|
Total non-operating expense, net (i) |
|
1,002 |
|
|
|
2,293 |
|
|
|
6,531 |
|
|
|
7,269 |
|
|
(Loss) income from operations |
|
(1,449 |
) |
|
|
976 |
|
|
|
(14,225 |
) |
|
|
(30,053 |
) |
|
|
|
|
|
|
|
|
||||||||||
Adjustments to (loss) income from operations: |
|
|
|
|
|
|
|
|||||||||
Operating depreciation and amortization |
|
1,104 |
|
|
|
1,221 |
|
|
|
4,568 |
|
|
|
4,534 |
|
|
Government contract revenue (ii) |
|
(5,942 |
) |
|
|
(6,574 |
) |
|
|
(21,051 |
) |
|
|
(30,430 |
) |
|
Direct expenses attributable to government contracts (iii) |
|
3,975 |
|
|
|
4,093 |
|
|
|
13,488 |
|
|
|
20,893 |
|
|
Share-based compensation (iv) |
|
5,504 |
|
|
|
4,903 |
|
|
|
22,867 |
|
|
|
20,271 |
|
|
Costs attributable to noncontrolling interest (v) |
|
82 |
|
|
|
124 |
|
|
|
85 |
|
|
|
334 |
|
|
Restructuring (vi) |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
3,728 |
|
|
Non-GAAP adjusted EBITDA |
$ |
3,274 |
|
|
$ |
4,743 |
|
|
$ |
5,732 |
|
|
$ |
(10,723 |
) |
- Includes interest income/expense and foreign exchange gains/losses.
- Represents revenue related to the cost reimbursement provisions under our government contracts.
- Represents the direct expenses attributable to work supporting government contracts, which are reimbursed and reflected under government contract revenue in the condensed consolidated statement of operations.
- Represents non-cash stock-based compensation.
-
Represents costs associated with the noncontrolling interest in Cerus Zhongbaokang (
Shandong ) Biomedical Co., LTD. - Represents costs associated with the Company’s restructuring plan implemented in June 2023.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250220080176/en/
Noopur Liffick
NBL LifeSci Advisory
925-298-2338
Source: Cerus Corporation
FAQ
What was Cerus 's (CERS) full-year 2024 product revenue growth?
How much did CERS improve its GAAP net loss in 2024?
What is Cerus 's (CERS) revenue guidance for 2025?
How much operating cash flow did CERS generate in 2024?